Today's Biotech Stocks to Watch: Bristol-Myers Squibb, Gilead Sciences and Merck & Co. Inc.

Morning movers in biotech and health care.

Apr 10, 2014 at 8:28AM


Let's take a look at today's top stories in biotech and health care. Keep an eye out for Bristol-Myers Squibb (NYSE:BMY)Gilead Sciences (NASDAQ:GILD) and Merck & Co. (NYSE:MRK)

Bristol-Myers reports strong late-stage results for its hepatitis C drug 
Bristol-Myers could be in for an green day after releasing late-stage results for its dual regimen (daclatasvir and asunaprevir) therapy for genotype 1b hepatitis C at the 49th Annual Meeting of the European Association for the Study of the Liver in London today. The therapy has already received breakthrough designation from the U.S. Food and Drug Administration, or FDA, as a combination therapy in the treatment of genotype 1b chronic hepatitis C and is presently under regulatory review for this indication, as well as other genotypes. Across a handful of patient populations, Bristol-Myers dual regimen therapy saw functional cure rates ranging from 82% to 90%.

Normally, such strong efficacy results would be hailed as a major achievement. However, these results are actually less impressive than those by competing drug's developed by AbbVie (NYSE:ABBV), Enanta Pharmaceuticals (NASDAQ:ENTA) and Gilead. Bristol-Myers' therapy also has a treatment duration double that of Gilead's drug Sovaldi for genotype 1 patients. So, while these results are impressive in their own right, the therapy's commercial prospects may be limited due to the presence of superior competitors in the market. 

Sovaldi continues to impress
Gilead Sciences also recently announced results from two open-label clinical trials for the company's hepatitis C drug Sovaldi, as a treatment for patients failing to respond to other direct-acting antivirals, or DAA's. In one study looking at patients with genotype 1 infections, treatment with Sovaldi plus weight-based ribavirin and pegylated interferon showed 74% cure rates in this hard to treat population. A second study looking at patients with genotypes 2 and 3 produced similar results. These data are being presented in London this week as well. Overall, these additional studies further show that Sovaldi is an excellent treatment option for hepatitis C, regardless of genotype or disease state.   

Merck's hepatitis C pill also makes waves in London
Also presenting in London, Merck released data on their all-oral hepatitis C therapy for newly treated patients. According to the company's press release, patients infected with genotype 1 and treated with Merck's oral therapy showed an impressive 98% cure rate. The drug will thus enter a pivotal late-stage trial soon based on these strong mid-stage results. Merck's shares are up 2% in premarket on the back of this news. 

Despite these strong results, you should keep in mind that Merck is well behind AbbVie, Bristol-Myers Squibb, Enanta Pharmaceuticals, and Gilead's competing drugs in terms of development. Specifically, Gilead's drug is already on the market with other formulations under regulatory review, and AbbVie and Bristol-Myer's offerings could also be on the market soon. And while some are championing Merck's pill as a potential top player in the field, I don't think this will be the case in the long-run. Sovaldi is an effective pan-genotype treatment and AbbVie's triple-therapy showed nearly 100% cure rates for genotype 1 in its clinical trials. Overall, Merck's drug has a ways to go before it can file for regulatory approval and test the commercial waters against these competing therapies.  

Boost your 2014 returns with The Motley Fool's top stock
There’s a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it’s one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

George Budwell owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information